The Motley Fool··Sara AppinoGLP-1 Boom Powers U.S. Pharma ETF Past Global Rival
U.S. pharma ETF IHE surged 39.70% on GLP-1 drug success while global healthcare ETF IXJ gained 10%, highlighting concentration versus diversification tradeoffs.
JNJABBVLLYIHEIXJportfolio concentrationGLP-1 drugs